IL2 and neoplasm: The EpCAM BiTE molecule effectively formed a binding interaction between EpCAM-positive tumor cells and CD3ε receptors on T cells, subsequently initiating the activation of naive T cells and the subsequent release of various pro-inflammatory factors, including IFN-γ, IL2, IL6, and IL10.